We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • Drug Products
    • Books
    • Books Library
    • Events
    • Form 483s
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
  • Device Products
    • Books
    • Books Library
    • Events
    • Form 483s
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » HOLLEY-COTEC LAUNCHES NEW ANTIMALARIAL DRUG IN KENYA

HOLLEY-COTEC LAUNCHES NEW ANTIMALARIAL DRUG IN KENYA

March 24, 2006

China-based drugmaker Holley-Cotec's duo-cotecxin, an antimalarial medication, was recently launched in Kenya, where 8.2 million new cases of the disease are reported each year. The drug is an artemisinin-based combination therapy (ACT) indicated for all forms of the disease.

"Over the last few years, there has been a paradigm shift in Africa towards universal adoption of [ACT]," said Kirana Bhatt, senior lecturer in the department of medicine at the University of Nairobi. She noted that in much of sub-Saharan Africa, "[ACTs] have yet to be adopted due to various reasons, financial constraint being a major one."

Duo-cotecxin is an association of a third-generation artemisinin derivative, dihydroartemisinin, and a new compound of the quinoleine group, piperaquine. It has been shown to be effective against falciparum malaria, the most dangerous form of the disease, in which infected red blood cells form microinfarctions in capillaries in the brain, liver, adrenal gland, intestinal tract, kidneys, lungs, and other organs.

KEYWORDS Daily International Pharma Alert

Upcoming Events

  • 10Jan

    Organizing Data and Document Archives: Finding a Needle in a Haystack for FDA Inspections

  • 12Feb

    Increase Compliance, Reduce Risk with Integrated Digital Solutions: Create a Connected System and Streamline...

  • 17Mar

    FDA Data Integrity: For Device and Pharma Firms, and Their Suppliers

  • 19Mar

    SOPs and Policies for the 21st Century: Why Less is More

  • 20Apr

    17th Annual Medical Device Quality Congress

Featured Products

  • Biological-risk-eval-and-mngmnt-for-md-130x160

    Biological Risk Evaluation and Management for Medical Devices

  • Gmp-inspection-preparation-checklist-130x160

    GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • 483sonline-logo-430x250

    483sOnline.com Your Personal Pre-inspection Toolkit

  • Globalmarketimage

    International Devices and Diagnostics Monitor

  • Cryolife_logo

    CryoLife’s Thoracoabdominal Stent Graft Receives CE Mark

  • Patentstablabel

    House Judiciary Committee Advances Patent Abuse Legislation

New!

17th Medical Device Quality Congress

Learn More Here
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578.

Copyright © 2019. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing